ClinicalTrials.gg
CompletedNCT03303105Updated Feb 17, 2023Results posted

Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine

A Phase 3 interventional study of TEV-48125 and TEV-48125 in Migraine, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-02-17.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 21 studies testing fremanezumab in Migraine Disorders — 1 open to participants now, 1 under way, none of them phase 3. fremanezumab · Migraine Disorders.

Enrollment
15th of 21
50 · median 292
Started
2017
with 3 others
Phase 3
9 of 21
none open now
Registered
6th of 21
by date
Lead sponsor
3 of 21
Otsuka Pharmaceutical Co., Ltd.

Among the 21 studies testing fremanezumab in Migraine Disorders, this one is the 15th largest by enrollment, is one of 4 that started in 2017, is one of 9 in phase 3, and was the 6th registered.

Migraine Disorders

1,659 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

1 of the 21 studies testing fremanezumab in Migraine Disorders is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fremanezumab

fremanezumab: first FDA approval 2018 (AJOVY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing fremanezumab in Migraine Disorders, or all of them as a file.
02

Study summary

To evaluate the long-term safety and tolerability of subcutaneous (SC) administration of TEV-48125 (at 225 mg once monthly [except for a loading dose of 675 mg for CM patients] or at 675 mg every 3 months) for the preventive treatment of Chronic Migraine and Episodic Migraine patients

03

Conditions studied

  • Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has a history of migraine (according to The International Classification of Headache Disorders, third edition [beta version] criteria) or clinical judgment suggests a migraine diagnosis
  • Patient fulfills the criteria for Chronic migraine or Episodic migraine in baseline information collected during the 28 day screening period
  • Not using preventive migraine medications for migraine or other medical conditions or using no more than 2 preventive migraine medication for migraine or other medical conditions if the dose and regimen have been stable for at least 2 months prior to giving .
  • Patient demonstrates compliance with the electronic headache diary during the screening period by entry of headache data on a minimum of 24 of 28 days and the entered data is judged appropriate by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Hematological, cardiac, renal, endocrine, pulmonary, gastrointestinal, genitourinary, neurologic, hepatic, or ocular disease considered in the judgment of the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    TEV-48125 (225 mg/1 month) group

    TEV-48125 will be administered subcutaneously once every 4 weeks for a total of 13 doses (at 225 mg once monthly \[except for a loading dose of 675 mg in subjects with CM\]).

    Drug: TEV-48125

  • Experimental
    TEV-48125 (675 mg/3 month) group

    TEV-48125 will be administered subcutaneously once every 12 weeks for a total of 5 doses (at 675 mg once every 3 months).

    Drug: TEV-48125

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With at Least One Treatment-Emergent Adverse Event (TEAE)

    * TEAEs are defined as the AEs that started after trial investigational medicinal product (IMP) treatment. Multiple occurrences of TEAEs are counted once per MedDRA preferred term. * Specific AE terms are provided in the Adverse Event section.

    Time frame: Baseline (Day 0) up to follow-up visit (Day 562)

Secondary outcomes

  1. Mean Change From Baseline in the Monthly (28 Day) Average Number of Migraine Days

    Headache-related efficacy endpoints were derived from headache variables collected using an eDiary. On each day, subjects entered headache data in the electronic headache diary for the previous 24-hour period. Subjects who had experienced headache on the previous day answered questions about the headache (ie, occurrence of headache, duration of headache, maximum severity of headache, presence/absence of associated symptoms, and use of acute headache medications). Overall headache duration was recorded numerically, in hours, as well as number of hours with headache of at least moderate severity. If headache was reported, then headache severity was subjectively rated by the subject as mild, moderate, or severe. Subjects also recorded the presence or absence of photophobia, phonophobia, nausea, or vomiting, and the status of use of any acute headache medications.

    Time frame: Baseline, Month 12

  2. Mean Change From Baseline in the Monthly (28 Day) Average Number of Headache Days of at Least Moderate Severity

    Headache-related efficacy endpoints were derived from headache variables collected using an eDiary. On each day, subjects entered headache data in the electronic headache diary for the previous 24-hour period. Subjects who had experienced headache on the previous day answered questions about the headache (ie, occurrence of headache, duration of headache, maximum severity of headache, presence/absence of associated symptoms, and use of acute headache medications). Overall headache duration was recorded numerically, in hours, as well as number of hours with headache of at least moderate severity. If headache was reported, then headache severity was subjectively rated by the subject as mild, moderate, or severe. Subjects also recorded the presence or absence of photophobia, phonophobia, nausea, or vomiting, and the status of use of any acute headache medications.

    Time frame: Baseline, Month 12

07

Results

Posted Jul 16, 2021

Participant flow

Participant flow — Overall Study
MilestoneTEV-48125 (225 mg/1 Month) GroupTEV-48125 (675 mg/3 Month) Group
Started2525
Completed2321
Not completed24
Withdrew: Adverse event02
Withdrew: Lack of efficacy10
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject02

Outcome measures

PrimaryPercentage of Subjects With at Least One Treatment-Emergent Adverse Event (TEAE)

* TEAEs are defined as the AEs that started after trial investigational medicinal product (IMP) treatment. Multiple occurrences of TEAEs are counted once per MedDRA preferred term. * Specific AE terms are provided in the Adverse Event section.

Time frame:
Baseline (Day 0) up to follow-up visit (Day 562)
Reported as:
Number · percentage of participants
Percentage of Subjects With at Least One Treatment-Emergent Adverse Event (TEAE)
percentage of participantsTEV-48125 (225 mg/1 Month) GroupTEV-48125 (675 mg/3 Month) Group
Percentage of Subjects With at Least One Treatment-Emergent Adverse Event (TEAE)92.088.0
SecondaryMean Change From Baseline in the Monthly (28 Day) Average Number of Migraine Days

Headache-related efficacy endpoints were derived from headache variables collected using an eDiary. On each day, subjects entered headache data in the electronic headache diary for the previous 24-hour period. Subjects who had experienced headache on the previous day answered questions about the headache (ie, occurrence of headache, duration of headache, maximum severity of headache, presence/absence of associated symptoms, and use of acute headache medications). Overall headache duration was recorded numerically, in hours, as well as number of hours with headache of at least moderate severity. If headache was reported, then headache severity was subjectively rated by the subject as mild, moderate, or severe. Subjects also recorded the presence or absence of photophobia, phonophobia, nausea, or vomiting, and the status of use of any acute headache medications.

Time frame:
Baseline, Month 12
Reported as:
Mean · days/month
Mean Change From Baseline in the Monthly (28 Day) Average Number of Migraine Days
days/monthTEV-48125 (225 mg/1 Month) GroupTEV-48125 (675 mg/3 Month) Group
Mean Change From Baseline in the Monthly (28 Day) Average Number of Migraine Days-5.9 ± 4.3-1.6 ± 5.7
SecondaryMean Change From Baseline in the Monthly (28 Day) Average Number of Headache Days of at Least Moderate Severity

Headache-related efficacy endpoints were derived from headache variables collected using an eDiary. On each day, subjects entered headache data in the electronic headache diary for the previous 24-hour period. Subjects who had experienced headache on the previous day answered questions about the headache (ie, occurrence of headache, duration of headache, maximum severity of headache, presence/absence of associated symptoms, and use of acute headache medications). Overall headache duration was recorded numerically, in hours, as well as number of hours with headache of at least moderate severity. If headache was reported, then headache severity was subjectively rated by the subject as mild, moderate, or severe. Subjects also recorded the presence or absence of photophobia, phonophobia, nausea, or vomiting, and the status of use of any acute headache medications.

Time frame:
Baseline, Month 12
Reported as:
Mean · days/month
Mean Change From Baseline in the Monthly (28 Day) Average Number of Headache Days of at Least Moderate Severity
days/monthTEV-48125 (225 mg/1 Month) GroupTEV-48125 (675 mg/3 Month) Group
Mean Change From Baseline in the Monthly (28 Day) Average Number of Headache Days of at Least Moderate Severity-4.3 ± 4.1-2.1 ± 4.1

Adverse events

Collected over Baseline (Day 0) up to follow-up visit (Day 562). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TEV-48125 (225 mg/1 Month) Group0/25 (0%)0/25 (0%)20/25 (80%)
TEV-48125 (675 mg/3 Month) Group0/25 (0%)2/25 (8%)16/25 (64%)
Most frequent serious events
Most frequent serious events
EventTEV-48125 (225 mg/1 Month) GroupTEV-48125 (675 mg/3 Month) Group
Rhegmatogenous retinal detachmentEye disorders0/251/25
Subarachnoid haemorrhageNervous system disorders0/251/25
Most frequent other events
Showing 10 of 11
Most frequent other events
EventTEV-48125 (225 mg/1 Month) GroupTEV-48125 (675 mg/3 Month) Group
NasopharyngitisInfections and infestations18/2514/25
Injection site erythemaGeneral disorders7/255/25
Injection site indurationGeneral disorders3/252/25
Injection site painGeneral disorders1/253/25
GastroenteritisInfections and infestations3/251/25
Injection site pruritusGeneral disorders2/251/25
InfluenzaInfections and infestations1/252/25
Oral herpesInfections and infestations1/252/25
Back painMusculoskeletal and connective tissue disorders1/252/25
CoughRespiratory, thoracic and mediastinal disorders1/252/25

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TEV-48125 (225 mg/1 Month) GroupTEV-48125 (675 mg/3 Month) GroupTotal
<=18 years000
Between 18 and 65 years242549
>=65 years101
Age, Continuous
Age, Continuous(years)TEV-48125 (225 mg/1 Month) GroupTEV-48125 (675 mg/3 Month) GroupTotal
Mean46.8 ± 7.945.8 ± 7.046.3 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)TEV-48125 (225 mg/1 Month) GroupTEV-48125 (675 mg/3 Month) GroupTotal
Female231942
Male268
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TEV-48125 (225 mg/1 Month) GroupTEV-48125 (675 mg/3 Month) GroupTotal
Japanese252550
Region of Enrollment
Region of Enrollment(Participants)TEV-48125 (225 mg/1 Month) GroupTEV-48125 (675 mg/3 Month) GroupTotal
Japan252550
08

Study locations

1 site
  • Saitama Medical University Hospital
    Iruma, Japan
09

References and documents

Publications

  • Sakai F, Suzuki N, Ning X, Ishida M, Usuki C, Iba K, Isogai Y, Koga N. Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study. Drug Saf. 2021 Dec;44(12):1355-1364. doi: 10.1007/s40264-021-01119-2. Epub 2021 Oct 23. PubMed 34687446 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Jun 2020, 30 months.

Results were first posted in Jul 2021, 1 year 1 month after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 30 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2017
First posted
Oct 5, 2017
StartActual
Dec 7, 2017
Primary completionActual
Jun 16, 2020
CompletionActual
Jun 16, 2020
Results first posted
Jul 16, 2021
Last update
Feb 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03303105
Responsible party
Sponsor
First posted
Oct 5, 2017
Start date
Dec 7, 2017
Primary completion
Jun 16, 2020
Completion
Jun 16, 2020
Results posted
Jul 16, 2021
Last update
Feb 17, 2023

Study contacts

Takehisa Matsumaru
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fremanezumab

Start the discussion